Back to top

Kepler Capital Reaffirms Their Buy Rating on Basilea Pharmaceutica (BSLN)

Kepler Capital analyst Christophe dombu maintained a Buy rating on Basilea Pharmaceutica on April 9 and set a price target of CHF69.00. The company...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Basilea Pharmaceutica AG (BPMUF)